CA/PRAK-IN-1
CA/PRAK-IN-1 is a dual inhibitor of carbonic anhydrase (Carbonic Anhydrase) and PRAK, with a Ki of 20.1 nM against hCA IX and 16.4 nM against hCA XII. CA/PRAK-IN-1 exhibits inhibitory activity against YES1 kinase, BTK, and MAP4K3. CA/PRAK-IN-1 induces G0/G1 phase arrest of the cancer cell cycle, inhibits DNA synthesis, disrupts hypoxia-driven survival pathways, promotes cell death, and shows broad-spectrum cytotoxicity against tumor cells. CA/PRAK-IN-1 can be used in research on various cancers including leukemia, colon cancer, melanoma, and renal cancer.
For research use only. We do not sell to patients.
- Formula: C26H21N3O5S
- Molecular Weight:487.53
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
hCA IX 20.1 nM (Ki) |
hCA XII 16.4 nM (Ki) |
GLK/MAP4K3 |
YES1 |
In Vitro
CA/PRAK-IN-1 (Compound 8d) potently and selectively inhibits tumor-associated human carbonic anhydrase isozymes IX (Ki = 20.1 nM) and XII (Ki = 16.4 nM), with significantly stronger inhibitory effects compared to the off-target isozymes I and II[1].
CA/PRAK-IN-1 (0.01-100 μM; 48 h) exhibits broad-spectrum antiproliferative activity against the NCI-60 panel of human tumor cell lines, with consistently low micromolar GI50 values ranging from 0.943 to 5.18 μM, and an overall panel MG-MID of 3.06 μM[1].
CA/PRAK-IN-1 maintains cytotoxic activity against MDA-MB-231 breast cancer cells under both normoxic (IC50 = 13.44 μM) and hypoxic (IC50 = 10.13 μM) conditions, while it shows low cytotoxicity against human normal fibroblast Wi-38 cells (IC50 = 16.25 μM)[1].
CA/PRAK-IN-1 (10 μM) inhibits key cancer-associated kinases, including PRAK (61% inhibition rate), YES1 (54% inhibition rate), BTK (52% inhibition rate), and MAP4K3 (52% inhibition rate)[1].
CA/PRAK-IN-1 (13.44 μM; 24 h) induces G0/G1 cell cycle arrest and inhibits DNA synthesis in MDA-MB-231 breast cancer cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:NCI-60 human tumor cell line panel
-
Concentration:10 μM (single-dose screening); 0.01-100 μM (five-dose testing)
-
Incubation Time:48 h
-
Result:Showed a mean growth inhibition percentage of 131% across the NCI-60 panel in single-dose screening at 10 μM.
Exhibited GI50 values ranging from 0.943 μM (RPMI-8226 leukemia cells) to 5.18 μM (OVCAR-4 ovarian cancer cells) in five-dose testing.
Exhibited notable activity with GI50 = 1.32 μM (CCRF-CEM leukemia cells), 1.59 μM (HCT-15 colon cancer cells), 1.55 μM (LOX IMVI melanoma cells), 1.26 μM (RXF 393 renal cancer cells), and 1.32 μM (MCF-7 breast cancer cells).
Demonstrated a full-panel MG-MID for GI50 of 3.06 μM.
-
Cell Line:MDA-MB-231 breast cancer cells
-
Concentration:13.44 μM
-
Incubation Time:24 h
-
Result:Increased the percentage of cells in the G0/G1 phase from 83.73% (control) to 96.18%.
Reduced the S phase population from 15.06% (control) to 2.63%.
Chemical Information
-
Molecular Weight 487.53
-
Formula C26H21N3O5S
-
SMILES
O=S(C1=CC=C(N2N=C(C(/C=C/C3=CC=C(OC)C=C3)=O)C(C(C4=CC=CC=C4)=O)=C2)C=C1)(N)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)